{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T03:42:28Z","timestamp":1791517348474,"version":"4.3.4"},"reference-count":87,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T00:00:00Z","timestamp":1707436800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\"><jats:title>Background<\/jats:title><jats:p>Cicatricial alopecia (CA) refers to various conditions that result in permanent hair loss. Treatment of CA has always been challenging. Regarding immune-mediated pathophysiology for many CA subtypes, the administration of Janus kinase (JAK) and tumor necrosis factor (TNF) inhibitors have potentiated the treatments of CA.<\/jats:p><\/jats:sec><jats:sec id=\"sec002\"><jats:title>Methods<\/jats:title><jats:p>After a thorough systematic search in PubMed\/Medline, Embase, Web of Science, Scopus, Google Scholar, ClinicalTrials.gov, and WHO ICTRP, a total of 3,532 relevant records were retrieved and screened. Accordingly, 56 studies met the eligibility criteria and entered the review.<\/jats:p><\/jats:sec><jats:sec id=\"sec003\"><jats:title>Results<\/jats:title><jats:p>Among JAK inhibitors, oral tofacitinib was the most frequently reported and the most effective treatment in improving signs and symptoms of CA with minimal adverse effects (AEs). Baricitinib was another JAK inhibitor with sustained improvement while causing mild AEs. As a TNF inhibitor, adalimumab induced a rapid and stable improvement in signs and symptoms in most patients with rare, tolerable AEs. Thalidomide was the other frequently reported yet controversial TNF inhibitor, which caused a rapid and significant improvement in the condition. However, it may result in mild to severe AEs, particularly neuropathies. Infliximab is a TNF inhibitor with mostly favorable results, albeit in a few patients caused treatable dermatological AEs. Apremilast and certolizumab pegol caused an incomplete amelioration of signs and symptoms with no AEs. Lenalidomide is another TNF inhibitor that can induce temporary improvement in CA with probable AEs. It is noteworthy that utilizing adalimumab, infliximab, etanercept, golimumab, and an anonymous TNF inhibitor has induced paradoxical CA and other A.E.s in some patients.<\/jats:p><\/jats:sec><jats:sec id=\"sec004\"><jats:title>Conclusion<\/jats:title><jats:p>Recent studies have recommended JAK and TNF inhibitors, especially oral tofacitinib and adalimumab, as a new modality or adjuvant therapy to previous medications for primary CA. Nonetheless, monitoring AEs on a regular basis is suggested, and further extensive studies are required before definitive recommendations.<\/jats:p><\/jats:sec>","DOI":"10.1371\/journal.pone.0293433","type":"journal-article","created":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T18:31:20Z","timestamp":1707503480000},"page":"e0293433","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":8,"title":["Tumor necrosis factor inhibitors and janus kinase inhibitors in the treatment of cicatricial alopecia: A systematic review"],"prefix":"10.1371","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6323-9252","authenticated-orcid":true,"given":"Nima","family":"Hajizadeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirhossein","family":"Heidari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Sadeghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1249-4429","authenticated-orcid":true,"given":"Azadeh","family":"Goodarzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2024,2,9]]},"reference":[{"issue":"1","key":"pone.0293433.ref001","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1067\/mjd.2003.68","article-title":"Summary of North American Hair Research Society (NAHRS)-sponsored Workshop on Cicatricial Alopecia, Duke University Medical Center, February 10 and 11, 2001.","volume":"48","author":"EA Olsen","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"pone.0293433.ref002","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/3-540-28691-8_48","volume-title":"Fortschritte der praktischen Dermatologie und Venerologie","author":"W Meigel","year":"2005"},{"issue":"4","key":"pone.0293433.ref003","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/ddg.13498","article-title":"Cicatricial alopecia","volume":"16","author":"V Kanti","year":"2018","journal-title":"JDDG: Journal der Deutschen Dermatologischen Gesellschaft."},{"issue":"9","key":"pone.0293433.ref004","doi-asserted-by":"crossref","first-page":"3666","DOI":"10.1073\/pnas.72.9.3666","article-title":"An endotoxin-induced serum factor that causes necrosis of tumors","volume":"72","author":"E Carswell","year":"1975","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"4","key":"pone.0293433.ref005","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1073\/pnas.61.4.1250","article-title":"Lymphocyte in vitro cytotoxicity: characterization of human lymphotoxin","volume":"61","author":"WP Kolb","year":"1968","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"1","key":"pone.0293433.ref006","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1093\/intimm\/dxu102","article-title":"Anti-TNF therapy: past, present and future","volume":"27","author":"C Monaco","year":"2015","journal-title":"Int Immunol"},{"issue":"4","key":"pone.0293433.ref007","doi-asserted-by":"crossref","first-page":"205","DOI":"10.5694\/j.1326-5377.2005.tb06998.x","article-title":"Tumour necrosis factor inhibitors","volume":"183","author":"PT Nash","year":"2005","journal-title":"Medical Journal of Australia"},{"issue":"12","key":"pone.0293433.ref008","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1002\/art.1780361206","article-title":"Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor \u03b1.","volume":"36","author":"MJ Elliott","year":"1993","journal-title":"Arthritis & Rheumatism."},{"issue":"3","key":"pone.0293433.ref009","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s40272-020-00394-3","article-title":"The Use of TNF\u03b1 Inhibitors in Treating Pediatric Skin Disorders.","volume":"22","author":"Q-BD Nguyen","year":"2020","journal-title":"Pediatric Drugs."},{"issue":"12","key":"pone.0293433.ref010","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/nrd.2017.201","article-title":"JAK inhibition as a therapeutic strategy for immune and inflammatory diseases.","volume":"16","author":"DM Schwartz","year":"2017","journal-title":"Nat Rev Drug Discov"},{"issue":"10","key":"pone.0293433.ref011","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1177\/1947601910397187","article-title":"Jak\/STAT pathways in cytokine signaling and myeloproliferative disorders: approaches for targeted therapies","volume":"1","author":"SS Jatiani","year":"2010","journal-title":"Genes Cancer"},{"issue":"3","key":"pone.0293433.ref012","doi-asserted-by":"crossref","first-page":"e184","DOI":"10.1016\/S2352-3026(19)30262-5","article-title":"Polycythaemia vera, ruxolitinib, and hydroxyurea: where do we go now?","volume":"7","author":"JL Spivak","year":"2020","journal-title":"Lancet Haematol"},{"issue":"6","key":"pone.0293433.ref013","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1093\/rheumatology\/key339","article-title":"Clinical significance of Janus Kinase inhibitor selectivity.","volume":"58","author":"EH Choy","year":"2019","journal-title":"Rheumatology (Oxford)."},{"issue":"4","key":"pone.0293433.ref014","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.jaad.2016.12.005","article-title":"JAK inhibitors in dermatology: The promise of a new drug class","volume":"76","author":"W Damsky","year":"2017","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"1","key":"pone.0293433.ref015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2133.2008.08591.x","article-title":"Management of primary cicatricial alopecias: Options for treatment","volume":"159","author":"MJ Harries","year":"2008","journal-title":"British Journal of Dermatology"},{"issue":"15","key":"pone.0293433.ref016","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1517\/14656566.2015.1084501","article-title":"Treatments options for alopecia.","volume":"16","author":"M Iorizzo","year":"2015","journal-title":"Expert Opinion on Pharmacotherapy"},{"issue":"1","key":"pone.0293433.ref017","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1080\/14728214.2018.1444750","article-title":"Emerging drugs for alopecia areata: JAK inhibitors.","volume":"23","author":"M Iorizzo","year":"2018","journal-title":"Expert opinion on emerging drugs."},{"issue":"4","key":"pone.0293433.ref018","doi-asserted-by":"crossref","first-page":"e2022178","DOI":"10.5826\/dpc.1204a178","article-title":"Various Application of Tofacitinib and Ruxolitinib (Janus Kinase Inhibitors) in Dermatology and Rheumatology: A Review of Current Evidence and Future Perspective.","volume":"12","author":"S Sadeghi","year":"2022","journal-title":"Dermatol Pract Concept."},{"key":"pone.0293433.ref019","author":"Blood Institute","year":"2014","journal-title":"Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies"},{"key":"pone.0293433.ref020","author":"Blood Institute","year":"2014","journal-title":"Quality Assessment Tool for Before-After (Pre-Post) Studies With No Control Group."},{"issue":"2","key":"pone.0293433.ref021","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1136\/bmjebm-2017-110853","article-title":"Methodological quality and synthesis of case series and case reports","volume":"23","author":"MH Murad","year":"2018","journal-title":"BMJ Evid Based Med"},{"issue":"6","key":"pone.0293433.ref022","doi-asserted-by":"crossref","first-page":"e12656","DOI":"10.1111\/dth.12656","article-title":"Tofacitinib for the treatment of lichen planopilaris: A case series.","volume":"31","author":"CC Yang","year":"2018","journal-title":"Dermatol Ther."},{"issue":"5","key":"pone.0293433.ref023","doi-asserted-by":"crossref","first-page":"S83","DOI":"10.1016\/j.jid.2018.03.498","article-title":"Efficacy of oral tofacitinib in the treatment of lichen planopilaris","volume":"138","author":"BN Sallee","year":"2018","journal-title":"Journal of Investigative Dermatology"},{"issue":"5","key":"pone.0293433.ref024","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1016\/j.jaad.2020.05.104","article-title":"Tofacitinib in the treatment of lichen planopilaris: A retrospective review","volume":"83","author":"J Plante","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"pone.0293433.ref025","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1159\/000505439","article-title":"Hair Loss in Lichen Planopilaris and Frontal Fibrosing Alopecia: Not Always Irreversible.","volume":"6","author":"P Batra","year":"2020","journal-title":"Skin Appendage Disord."},{"issue":"5","key":"pone.0293433.ref026","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/j.jid.2017.02.088","article-title":"Clinical investigation of JAK inhibitor Tofacitinib in scarring alopecias","volume":"137","author":"L Bordone","year":"2017","journal-title":"Journal of Investigative Dermatology"},{"issue":"3","key":"pone.0293433.ref027","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.jaad.2022.02.027","article-title":"Treatment of lichen planopilaris with baricitinib: A retrospective study","volume":"87","author":"A Moussa","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"pone.0293433.ref028","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1001\/jamadermatol.2019.0140","article-title":"Oral Tofacitinib Treatment of Erosive Pustular Dermatosis of the Scalp","volume":"155","author":"N Leung","year":"2019","journal-title":"JAMA Dermatol"},{"issue":"4","key":"pone.0293433.ref029","doi-asserted-by":"crossref","first-page":"AB204","DOI":"10.1016\/j.jaad.2019.06.751","article-title":"Erosive pustular dermatosis of the scalp: A successful treatment with oral tofacitinib","volume":"81","author":"H Eldik","year":"2019","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"6","key":"pone.0293433.ref030","doi-asserted-by":"crossref","DOI":"10.1111\/dth.13968","article-title":"Folliculitis decalvans responsive to tofacitinib: A case series.","volume":"33","author":"R Jerjen","year":"2020","journal-title":"Dermatologic Therapy."},{"issue":"3","key":"pone.0293433.ref031","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.jdcr.2019.12.016","article-title":"Treatment of lichen planopilaris with adalimumab in a patient with hidradenitis suppurativa and rheumatoid arthritis.","volume":"6","author":"MS Alam","year":"2020","journal-title":"JAAD Case Rep"},{"issue":"1","key":"pone.0293433.ref032","first-page":"74","article-title":"Therapy-resistant folliculitis decalvans and lichen planopilaris successfully treated with adalimumab.","volume":"12","author":"K Kreutzer","year":"2014","journal-title":"J Dtsch Dermatol Ges"},{"issue":"3","key":"pone.0293433.ref033","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/S0190-9622(03)00849-1","article-title":"Thalidomide is ineffective in the treatment of lichen planopilaris","volume":"51","author":"C Jouanique","year":"2004","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"pone.0293433.ref034","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1067\/mjd.2001.119559","article-title":"Lichen planopilaris treated with thalidomide","volume":"45","author":"SJ George","year":"2001","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"6","key":"pone.0293433.ref035","doi-asserted-by":"crossref","first-page":"241","DOI":"10.4103\/ijt.ijt_92_19","article-title":"Therapy-Recalcitrant Folliculitis Decalvans Controlled Successfully with Adalimumab.","volume":"11","author":"MM Alhameedy","year":"2019","journal-title":"Int J Trichology."},{"issue":"3","key":"pone.0293433.ref036","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.jaad.2022.02.044","article-title":"Refractory folliculitis decalvans treated with adalimumab: A case series of 23 patients","volume":"87","author":"M Iorizzo","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"pone.0293433.ref037","doi-asserted-by":"crossref","first-page":"240","DOI":"10.4103\/ijt.ijt_34_18","article-title":"A Case of Isotretinoin Therapy-Refractory Folliculitis Decalvans Treated Successfully with Biosimilar Adalimumab (Exemptia).","volume":"10","author":"F Shireen","year":"2018","journal-title":"Int J Trichology."},{"issue":"3","key":"pone.0293433.ref038","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/dth.12222","article-title":"Off-label use of TNF-alpha inhibitors in a dermatological university department: retrospective evaluation of 118 patients.","volume":"28","author":"FL Sand","year":"2015","journal-title":"Dermatol Ther."},{"issue":"10","key":"pone.0293433.ref039","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.jdcr.2020.08.019","article-title":"Successful treatment of refractory folliculitis decalvans with apremilast.","volume":"6","author":"M F\u00e4ssler","year":"2020","journal-title":"JAAD Case Rep"},{"issue":"8","key":"pone.0293433.ref040","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1111\/j.1610-0387.2012.07972.x","article-title":"Successful use of infliximab in a patient with recalcitrant folliculitis decalvans.","volume":"10","author":"N Mihaljevi\u0107","year":"2012","journal-title":"J Dtsch Dermatol Ges"},{"key":"pone.0293433.ref041","first-page":"762035","article-title":"Eruptive condyloma accuminata after initiation of infliximab treatment for folliculitis decalvans.","volume":"2013","author":"DC Wu","year":"2013","journal-title":"Case Rep Dermatol Med"},{"issue":"1","key":"pone.0293433.ref042","first-page":"e26","article-title":"Therapy-refractory folliculitis decalvans treated with certolizumab pegol","volume":"61","author":"M Hoy","year":"2022","journal-title":"Int J Dermatol"},{"key":"pone.0293433.ref043","doi-asserted-by":"crossref","first-page":"S84","DOI":"10.1016\/j.clim.2010.03.253","article-title":"Efficacy of adalimumab for the treatment of dissecting cellulitis of the scalp and disseminated granuloma annulare","volume":"135","author":"M Hession","year":"2010","journal-title":"Clin Immunol"},{"issue":"5 SUPPL","key":"pone.0293433.ref044","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.1067\/mjd.2003.149","article-title":"Thalidomide for treatment of severe generalized discoid lupus lesions in two patients with systemic lupus erythematosus","volume":"48","author":"A Alfadley","year":"2003","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"2","key":"pone.0293433.ref045","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1111\/j.1365-2133.2008.08674.x","article-title":"Perifolliculitis capitis abscedens et suffodiens successfully controlled with infliximab","volume":"159","author":"HR Brandt","year":"2008","journal-title":"Br J Dermatol"},{"issue":"2","key":"pone.0293433.ref046","article-title":"Dissecting cellulitis of the scalp in patients with hidradenitis suppurativa respondinig to adalimumab therapy","volume":"12","author":"JM Cautela","year":"2020","journal-title":"Journal of the Dermatology Nurses\u2019 Association"},{"key":"pone.0293433.ref047","doi-asserted-by":"crossref","DOI":"10.7573\/dic.2021-9-8","article-title":"Thalidomide and discoid lupus erythematosus: case series and review of literature.","volume":"11","author":"G Malara","year":"2022","journal-title":"Drugs Context"},{"issue":"4","key":"pone.0293433.ref048","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1111\/bjd.14269","article-title":"Dissecting cellulitis of the scalp treated with tumour necrosis factor-alpha inhibitors: experience with two agents","volume":"174","author":"Y Mansouri","year":"2016","journal-title":"British Journal of Dermatology"},{"issue":"2","key":"pone.0293433.ref049","first-page":"102","article-title":"Refractory dissecting Cellulitis of the Scalp Successfully controlled with adalimumab.","volume":"34","author":"RF Martin-Garc\u00eda","year":"2015","journal-title":"P R Health Sci J"},{"issue":"3","key":"pone.0293433.ref050","first-page":"255","article-title":"Perifolliculitis capitis abscedens et suffodiens treated with anti-tumor necrosis factor-alpha\u2013Possible new treatment option.","volume":"26","author":"IS Masnec","year":"2018","journal-title":"Acta Dermatovenerol Croat"},{"issue":"8","key":"pone.0293433.ref051","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1111\/ced.14789","article-title":"Hidradenitis suppurativa with perifolliculitis capitis abscedens et suffodiens successfully treated with a human anti-tumour necrosis factor monoclonal antibody","volume":"46","author":"S Minakawa","year":"2021","journal-title":"Clin Exp Dermatol"},{"issue":"5","key":"pone.0293433.ref052","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1001\/archdermatol.2010.16","article-title":"3 cases of dissecting cellulitis of the scalp treated with adalimumab: control of inflammation within residual structural disease","volume":"146","author":"AA Navarini","year":"2010","journal-title":"Arch Dermatol"},{"issue":"2","key":"pone.0293433.ref053","doi-asserted-by":"crossref","DOI":"10.1111\/dth.14829","article-title":"The role of biologic treatment in special scenarios in hidradenitis suppurativa: Facial and nape phenotype, dissecting cellulitis of the scalp, and lymphedema.","volume":"34","author":"M Sanchez-Diaz","year":"2021","journal-title":"Dermatologic Therapy."},{"issue":"3","key":"pone.0293433.ref054","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1093\/rheumatology\/36.3.353","article-title":"Thalidomide in the treatment of the cutaneous manifestations of lupus erythematosus: experience in sixteen consecutive patients","volume":"36","author":"RJ Stevens","year":"1997","journal-title":"Br J Rheumatol"},{"issue":"3","key":"pone.0293433.ref055","first-page":"AB52","article-title":"Dissecting cellulitis of the scalp treated with adalimumab","volume":"60","author":"S Sukhatme","year":"2009","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"9","key":"pone.0293433.ref056","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1111\/1346-8138.14998","article-title":"Perifolliculitis capitis abscedens et suffodiens treatment with tumor necrosis factor inhibitors: A case report and review of published cases","volume":"46","author":"T Takahashi","year":"2019","journal-title":"J Dermatol"},{"issue":"4","key":"pone.0293433.ref057","first-page":"36","article-title":"Dissecting Cellulitis of the Scalp Responding to Intravenous Tumor Necrosis Factor-alpha Antagonist.","volume":"5","author":"U Wollina","year":"2012","journal-title":"J Clin Aesthet Dermatol."},{"key":"pone.0293433.ref058","doi-asserted-by":"crossref","first-page":"455","DOI":"10.2147\/CCID.S301451","article-title":"Recalcitrant Dissecting Cellulitis of the Scalp Treated Successfully with Adalimumab with Hair Regrowth: A Case Report.","volume":"14","author":"A Alsantali","year":"2021","journal-title":"Clin Cosmet Investig Dermatol."},{"issue":"8","key":"pone.0293433.ref059","doi-asserted-by":"crossref","first-page":"e374","DOI":"10.1111\/1346-8138.15945","article-title":"Perifolliculitis capitis abscedens et suffodiens with hidradenitis suppurativa and nodulocystic acne treated with adalimumab","volume":"48","author":"I. Kurokawa","year":"2021","journal-title":"J Dermatol"},{"issue":"7\u20138","key":"pone.0293433.ref060","doi-asserted-by":"crossref","first-page":"e1309","DOI":"10.1093\/milmed\/usz394","article-title":"A Case Report of Tumor Necrosis Factor Alpha Inhibitors in an Active Duty Service Member with Dissecting Cellulitis of the Scalp Resistant to Treatment.","volume":"185","author":"E Maxon","year":"2020","journal-title":"Mil Med."},{"issue":"4","key":"pone.0293433.ref061","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/j.1365-2133.1983.tb04600.x","article-title":"Thalidomide in the treatment of sixty cases of chronic discoid lupus erythematosus","volume":"108","author":"J Knop","year":"1983","journal-title":"Br J Dermatol"},{"issue":"2","key":"pone.0293433.ref062","doi-asserted-by":"crossref","first-page":"155","DOI":"10.29021\/spdv.79.2.1283","article-title":"Discoid Lupus Erythematosus of the Scalp in a Patient with Systemic Lupus Erythematosus: A Case Report with Complete Hair Regrowth.","volume":"79","author":"C Garbelini-Lima","year":"2021","journal-title":"Journal of the Portuguese Society of Dermatology and Venereology"},{"issue":"1","key":"pone.0293433.ref063","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/pde.14067","article-title":"Rapid response to treatment with thalidomide in an adolescent with generalized discoid lupus erythematosus","volume":"37","author":"B Tran","year":"2020","journal-title":"Pediatric Dermatology"},{"issue":"3","key":"pone.0293433.ref064","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1001\/archdermatol.2009.30","article-title":"Lenalidomide for the treatment of resistant discoid lupus erythematosus","volume":"145","author":"A Shah","year":"2009","journal-title":"Archives of Dermatology"},{"issue":"3","key":"pone.0293433.ref065","doi-asserted-by":"crossref","DOI":"10.1111\/dth.13364","article-title":"Discoid drug-induced lupus erythematosus induced by antitumor necrosis factor agents is a very rare subtype of cutaneous lupus: Three cases and literature review.","volume":"33","author":"A Brehon","year":"2020","journal-title":"Dermatologic Therapy"},{"issue":"2","key":"pone.0293433.ref066","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1002\/ibd.20954","article-title":"Adalimumab-induced psoriasis of the scalp with diffuse alopecia: a severe potentially irreversible cutaneous side effect of TNF-alpha blockers.","volume":"16","author":"L El Shabrawi-Caelen","year":"2010","journal-title":"Inflammatory Bowel Dis"},{"key":"pone.0293433.ref067","first-page":"122","article-title":"Lichen planopilaris: The paradoxical role of tumour necrosis factor a antagonists","volume":"169","author":"M Walsh","year":"2013","journal-title":"British Journal of Dermatology"},{"issue":"3","key":"pone.0293433.ref068","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1684\/ejd.2018.3270","article-title":"Persistent neutrophilic scarring alopecia triggered by anti-TNF blockade for Crohn\u2019s disease","volume":"28","author":"K Amschler","year":"2018","journal-title":"Eur J Dermatol"},{"issue":"2","key":"pone.0293433.ref069","first-page":"e143","article-title":"Case report of lichen planopilaris occurring in a pediatric patient receiving a tumor necrosis factor \u03b1 inhibitor and a review of the literature.","volume":"33","author":"PSA Jayasekera","year":"2016","journal-title":"Pediatric Dermatology"},{"issue":"9","key":"pone.0293433.ref070","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1345\/aph.1P079","article-title":"Infliximab-induced lichen planopilaris","volume":"44","author":"R Fern\u00e1ndez-Torres","year":"2010","journal-title":"Ann Pharmacother"},{"key":"pone.0293433.ref071","doi-asserted-by":"crossref","first-page":"2050313x20901967.","DOI":"10.1177\/2050313X20901967","article-title":"Lichen planopilaris induced by infliximab: A case report.","volume":"8","author":"ML McPhie","year":"2020","journal-title":"SAGE Open Med Case Rep."},{"issue":"4","key":"pone.0293433.ref072","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s13555-016-0156-z","article-title":"Severe Infliximab-Induced Alopecia and Scalp Psoriasis in a Woman with Crohn\u2019s Disease: Dramatic Improvement after Drug Discontinuation and Treatment with Adjuvant Systemic and Topical Therapies.","volume":"6","author":"J Udkoff","year":"2016","journal-title":"Dermatol Ther (Heidelb)."},{"issue":"1","key":"pone.0293433.ref073","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/j.1525-1470.2008.00847.x","article-title":"Lichen planopilaris noted during etanercept therapy in a child with severe psoriasis.","volume":"26","author":"NR Abbasi","year":"2009","journal-title":"Pediatr Dermatol"},{"issue":"5","key":"pone.0293433.ref074","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1111\/j.1365-2133.2008.08529.x","article-title":"Onset of lichen planopilaris during treatment with etanercept","volume":"158","author":"S Garcovich","year":"2008","journal-title":"Br J Dermatol"},{"issue":"6","key":"pone.0293433.ref075","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1046\/j.1365-2230.2003.01411.x","article-title":"Etanercept-induced systemic lupus erythematosus","volume":"28","author":"VJ Swale","year":"2003","journal-title":"Clin Exp Dermatol"},{"issue":"1","key":"pone.0293433.ref076","article-title":"Alopecia areata and scarring alopecia presenting during golimumab therapy for ankylosing spondylitis","volume":"11","author":"MM Helm","year":"2018","journal-title":"North American Journal of Medicine and Science"},{"issue":"6","key":"pone.0293433.ref077","first-page":"560","article-title":"TNF-alpha induced scarring psoriatic alopecia mimicking lichen planopilaris: A clinical-pathological-dermoscopic case correlation: Clinical symposium","volume":"19","author":"YM Lenzy","year":"2010","journal-title":"Experimental Dermatology"},{"key":"pone.0293433.ref078","article-title":"The efficacy and safety of JAK inhibitors for alopecia areata: A systematic review and meta-analysis of prospective studies.","volume":"13","author":"D Yan","year":"2022","journal-title":"Front Pharmacol."},{"issue":"8","key":"pone.0293433.ref079","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1007\/s40265-013-0065-8","article-title":"Tofacitinib: a review of its use in adult patients with rheumatoid arthritis.","volume":"73","author":"LJ Scott","year":"2013","journal-title":"Drugs"},{"issue":"5","key":"pone.0293433.ref080","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1111\/jdv.15489","article-title":"JAK inhibitors for alopecia areata: a systematic review and meta-analysis.","volume":"33","author":"K Phan","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"pone.0293433.ref081","first-page":"e13053","article-title":"The role of Janus kinase inhibitors in the treatment of alopecia areata: A systematic review.","volume":"32","author":"AB de Oliveira","year":"2019","journal-title":"Dermatologic Therapy."},{"issue":"8","key":"pone.0293433.ref082","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1080\/09546634.2022.2133956","article-title":"Efficacy and safety of JAK inhibitors in the treatment of alopecia areata in children: a systematic review and meta-analysis.","volume":"33","author":"Y Chen","year":"2022","journal-title":"J Dermatolog Treat"},{"issue":"5","key":"pone.0293433.ref083","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1111\/pde.14712","article-title":"Paradoxical psoriasis in pediatric patients: A systematic review.","volume":"38","author":"BM Cyrenne","year":"2021","journal-title":"Pediatric Dermatology"},{"issue":"2","key":"pone.0293433.ref084","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.jaad.2016.08.012","article-title":"Tumor necrosis factor-\u03b1 inhibitor-induced psoriasis: Systematic review of clinical features, histopathological findings, and management experience","volume":"76","author":"G Brown","year":"2017","journal-title":"Journal of the American Academy of Dermatology"},{"key":"pone.0293433.ref085","volume-title":"StatPearls","author":"V Gerriets","year":"2023"},{"issue":"4","key":"pone.0293433.ref086","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1111\/ced.15019","article-title":"The role of thalidomide in dermatology","volume":"47","author":"K Hussain","year":"2022","journal-title":"Clin Exp Dermatol"},{"key":"pone.0293433.ref087","first-page":"523","volume-title":"In: Encyclopedia of Toxicology","author":"G K","year":"2014"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0293433","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,10]],"date-time":"2024-11-10T23:44:53Z","timestamp":1731282293000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0293433"}},"subtitle":[],"editor":[{"given":"Shuo-Yan","family":"Gau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,2,9]]},"references-count":87,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,2,9]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0293433","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,9]]}}}